Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

Core Insights - Oculis Holding AG is presenting its innovative late-stage pipeline at major ophthalmology conferences, including Eyecelerator 2025, ARVO Annual Meeting, and Retina World Congress [1][2][3] Pipeline Developments - The DME AWARE Delphi Study interim results will focus on unmet needs in diabetic macular edema (DME) patient management, with insights from the Phase 3 DIAMOND program on OCS-01 eye drops [2][7] - OCS-01 is being developed as the first non-invasive treatment for DME, addressing the need for earlier intervention and for patients who do not respond adequately to current treatments [2][13] - Licaminlimab (OCS-02) is being investigated for dry eye disease (DED) and has shown positive results in Phase 2 trials, with a genetic biomarker identified to predict patient response [3][16] Conference Presentations - Oculis will showcase its developments at the following events: - Eyecelerator 2025 on May 2, 2025, featuring TKI and Drug Delivery [4] - ARVO Annual Meeting on May 5, 2025, presenting interim results of the DME AWARE Delphi Study [7] - Retina World Congress on May 8, 2025, discussing Licaminlimab in DED treatment [7] Market Context - DME currently affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [15] - DED impacts over 110 million people in G7 countries, with a significant portion of patients remaining unsatisfied with current treatment options [18][19] Company Overview - Oculis is a biopharmaceutical company focused on addressing significant unmet medical needs in ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for DME and Licaminlimab for DED [20]